Pharmacokinetics (PK) and tolerability of single and multiple doses of bosentan, an oral dual endothlein receptor antagonist, in children with pulmonary arterial hypertension

被引：0
|
作者：
Barst, RJ
Ivy, D
Widlitz, AC
Moore, K
Doran, A
van Giersbergen, P
Nguyen, N
Gaitonde, MD
机构：
[1] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[2] Univ Colorado, Childrens Hosp, Denver, CO 80202 USA
[3] Actelion Pharmaceut Ltd, Allschwil, Switzerland
来源：
CIRCULATION | 2002年 / 106卷 / 19期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2239
引用
收藏
页码：450 / 450
页数：1
相关论文
共 50 条
  • [31] Safety, tolerability and pharmacokinetics (PK) of multiple doses of lecozotan, a novel 5HT1A antagonist, in healthy elderly subjects.
    Parks, V
    Raje, SV
    Patat, AA
    Plotka, A
    Astruc, B
    Chassard, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P68 - P68
  • [32] Single- and Multiple-Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, in Adults
    Han, Tae H.
    Blanchard, Rebecca L.
    Palcza, John
    McCrea, Jacqueline B.
    Laethem, Tine
    Willson, Kenneth
    Xu, Yang
    Ermlich, Susan
    Boyle, Janet
    Lines, Christopher
    Gutierrez, Maria
    Van Bortel, Luc
    Xiao, Alan J.
    Sinclair, Simon
    Hickey, Lisa
    Panebianco, Deborah
    Murphy, M. Gail
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (12): : 1367 - 1376
  • [33] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
    Channick, RN
    Simonneau, G
    Sitbon, O
    Robbins, IM
    Frost, A
    Tapson, VF
    Badesch, DB
    Roux, S
    Rainisio, M
    Bodin, F
    Rubin, LJ
    LANCET, 2001, 358 (9288): : 1119 - 1123
  • [34] EVALUATION OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF MULTIPLE ORAL DOSES OF CC-220 IN HEALTHY SUBJECTS.
    Thomas, M. E.
    Ye, Y.
    Weiss, D.
    Gaudy, A.
    Chen, N.
    Yang, Z.
    Liu, L.
    Schafer, P. H.
    Mandarino, D.
    Palmisano, M.
    O'Mara, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S22 - S22
  • [35] Pharmacokinetics and safety profile of a novel formulation of bosentan in children with pulmonary arterial hypertension (PAH): FUTURE-1 study
    Beghetti, M.
    Haworth, S. G.
    Barst, R. J.
    Jais, X.
    Acar, P.
    Fraisse, A.
    Ivy, D.
    Schulze-Neick, I.
    Bonnet, D.
    Berger, R. M. F.
    EUROPEAN HEART JOURNAL, 2007, 28 : 150 - 150
  • [36] A safety, tolerability, and pharmacokinetics (PK) study of single and multiple doses of lecozotan sustained release (SR), a novel S-HT1A antagonist, in healthy young subjects
    Raja, S.
    Parks, V.
    Plotka, A.
    Patas, A.
    Paul, J.
    Chalon, S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1121 - 1121
  • [37] Tracleer (bosentan), a dual endothelin receptor antagonist (ERA), for the treatment of pulmonary arterial hypertension (PAH) related to connective tissue diseases: Effect on quality of life (QoL)
    Proudman, S
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S692 - S692
  • [38] Novel Dual Endothelin Receptor Antagonist Macitentan Reverses Severe Pulmonary Arterial Hypertension in Rats
    Kunita-Takanezawa, Mutsumi
    Abe, Kohtaro
    Hirooka, Yoshitaka
    Kuwabara, Yukimitsu
    Hirano, Katsuya
    Oka, Masahiko
    Sunagawa, Kenji
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (05) : 473 - 480
  • [39] Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
    Belge, Catharina
    Delcroix, Marion
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [40] Endothelin-1 dual receptor antagonist and the effect on platelet function in pulmonary arterial hypertension
    Davidson, S. J.
    Wort, S. J.
    Parfitt, L. A.
    Corte, T. J.
    Park, J.
    Harries, C.
    Gatzoulis, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 901 - 901
12345